Home / Resource Library / Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Brutons Tyrosine Kinase Inhibitor Therapy
Multicenter Study of Mantle Cell Lymphoma Outcomes Following First-Line Bendamustine-Rituximab and Second-Line Brutons Tyrosine Kinase Inhibitor Therapy